- Home
- RELI vs APVO Comparison
RELI vs APVO Comparison
Compare RELI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELI
- APVO
- Stock Information
- Founded
- RELI 2013
- APVO 2016
- Country
- RELI United States
- APVO United States
- Employees
- RELI N/A
- APVO N/A
- Industry
- RELI Specialty Insurers
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- RELI Finance
- APVO Health Care
- Exchange
- RELI Nasdaq
- APVO Nasdaq
- Market Cap
- RELI 3.5M
- APVO 4.1M
- IPO Year
- RELI N/A
- APVO N/A
- Fundamental
- Price
- RELI $2.12
- APVO $3.23
- Analyst Decision
- RELI
- APVO Strong Buy
- Analyst Count
- RELI 0
- APVO 1
- Target Price
- RELI N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- RELI 3.6M
- APVO 6.6M
- Earning Date
- RELI 07-24-2025
- APVO 08-07-2025
- Dividend Yield
- RELI N/A
- APVO N/A
- EPS Growth
- RELI N/A
- APVO N/A
- EPS
- RELI N/A
- APVO N/A
- Revenue
- RELI $14,208,143.00
- APVO N/A
- Revenue This Year
- RELI N/A
- APVO N/A
- Revenue Next Year
- RELI N/A
- APVO N/A
- P/E Ratio
- RELI N/A
- APVO N/A
- Revenue Growth
- RELI 2.40
- APVO N/A
- 52 Week Low
- RELI $0.97
- APVO $2.81
- 52 Week High
- RELI $5.11
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- RELI 61.88
- APVO 34.28
- Support Level
- RELI $1.88
- APVO $2.81
- Resistance Level
- RELI $2.60
- APVO $13.11
- Average True Range (ATR)
- RELI 0.36
- APVO 1.10
- MACD
- RELI 0.08
- APVO 0.30
- Stochastic Oscillator
- RELI 52.85
- APVO 4.08
About RELI Reliance Global Group Inc.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.